Surrogate Endpoint For Pediatric PAH Gets Advisory Panel OK, But Validation Process Draws Concern
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer can use a hemodynamic endpoint in pediatric trials of Revatio (sildenafil), but FDA's Cardiovascular and Renal Drugs Advisory Committee expresses enough ambiguity to spoil the precedent.